Autoimmune thyroid disease and pregnancy: relevance for the child.
As a group, the autoimmune thyroid diseases, including Graves' disease, Hashimoto's thyroiditis, and primary myxedema, are among the most common endocrine disorders encountered during pregnancy. Therefore, a substantial number of offspring will grow and develop in utero under conditions of maternal autoimmune thyroid disease and may be exposed to abnormal maternal thyroid function, maternal thyroid antibodies, and/or numerous therapeutic agents used to manage maternal thyroid dysfunction. This article reviews the effects that these various aspects of maternal autoimmune thyroid disorders can have on pregnancy outcome, as well as on the physical growth, neuropsychological development, and thyroid status of the developing fetus and neonate.
Dallas
John S
JS
Department of Pediatrics, University of Texas Medical Branch-Galveston, Galveston, TX 77555-0363, USA. jdallas@utmb.edu
D013956:Antithyroid Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood; D005314:Embryonic and Fetal Development; D005260:Female; D006111:Graves Disease / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008431:Maternal-Fetal Exchange; D009230:Myxedema / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D011256:Pregnancy Outcome; D013959:Thyroid Diseases / Q000151:congenital / Q000276:immunology / Q000628:therapy; D013967:Thyroiditis, Autoimmune / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology
D013956:Antithyroid Agents; D001323:Autoantibodies